Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Clinical pharmacology and therapy

• Publication date

  2018-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cpt.1007PMID 29385237PMCID PMC5931215
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacogenomics and Personalized Medicine

  2020cited by this paper
• Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen

  2017cited by this paper
• CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study

  2017cited by this paper
• Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer

  2017cited by this paper
• CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset

  2017cited by this paper
• The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems

  2017cited by this paper
• Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism

  2017cited by this paper
• Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1

  2016cited by this paper
• Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients

  2016cited by this paper
• Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC)

  2016cited by this paper
• Prediction of CYP2D6 phenotype from genotype across world populations

  2016cited by this paper
• Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients.

  2016cited by this paper
• Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.

  2016influential reference
• Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study

  2016cited by this paper
• Association of CYP2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese population.

  2016cited by this paper
• Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen

  2015cited by this paper
• Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

  2015cited by this paper
• Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C Polymorphisms and Overall Survival of Breast Cancer Patients after Tamoxifen Therapy

  2015cited by this paper
• Functional characterization of CYP2D6 enhancer polymorphisms.

  2015cited by this paper
• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

  2015cited by this paper
• Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

  2015cited by this paper
• CYP3A4*22 is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen.

  2015cited by this paper
• Contribution of ABCB1 and CYP2D6 genotypes to the outcome of tamoxifen adjuvant treatment in premenopausal women with breast cancer.

  2015cited by this paper
• Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies.

  2015cited by this paper
• Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer

  2015cited by this paper
• Contribution of ABCB 1 and CYP 2 D 6 Genotypes to the Outcome of Tamoxifen Adjuvant Treatment in Premenopausal Women With Breast Cancer

  2015cited by this paper
• Relative Contributions of Cytochrome CYP3A4 Versus CYP3A5 for CYP3A-Cleared Drugs Assessed In Vitro Using a CYP3A4-Selective Inactivator (CYP3cide)

  2014cited by this paper
• Functional characterization of wild-type and 49 CYP2D6 allelic variants for N-desmethyltamoxifen 4-hydroxylation activity.

  2014cited by this paper
• A prospective multicenter study

  2014cited by this paper
• Association of CYP2C19 polymorphisms with survival of breast cancer patients using tamoxifen: results of a meta- analysis.

  2014cited by this paper
• Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.

  2014cited by this paper
• Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

  2014cited by this paper
• Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update

  2014cited by this paper
• Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer

  2014cited by this paper
• Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

  2014cited by this paper
• No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients

  2014cited by this paper
• Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy

  2014cited by this paper
• Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer

  2014cited by this paper
• Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes

  2014cited by this paper
• Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22

  2014cited by this paper
• CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations

  2013cited by this paper
• CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer

  2013cited by this paper
• CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial

  2013cited by this paper
• Complexities of CYP2D6 gene analysis and interpretation

  2013cited by this paper
• Clinical pharmacology and therapeutics.

  2013cited by this paper
• Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice

  2013cited by this paper
• CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial

  2013cited by this paper
• Development and use of active clinical decision support for preemptive pharmacogenomics

  2013cited by this paper
• CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment

  2013cited by this paper
• Relationship between Genotypes Sult1a2 and Cyp2d6 and Tamoxifen Metabolism in Breast Cancer Patients

  2013cited by this paper
• PharmGKB summary: tamoxifen pathway, pharmacokinetics

  2013cited by this paper
• Electronic health record design and implementation for pharmacogenomics: a local perspective

  2013cited by this paper
• The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future

  2013cited by this paper
• Role and pharmacologic significance of cytochrome P‐450 2D6 in oxidative metabolism of toremifene and tamoxifen

  2013cited by this paper
• CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.

  2013cited by this paper
• The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real‐World Implementation

  2013cited by this paper
• Common CYP 2 D 6 polymorphisms affecting alternative splicing and transcription : long-range haplotypes with two regulatory variants modulate CYP 2 D 6 activity

  2013cited by this paper
• BREAST CANCER PATIENTS;

  2013cited by this paper
• Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.

  2012cited by this paper
• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype

  2012cited by this paper
• Effect of CYP2D6 polymorphisms on breast cancer recurrence

  2012cited by this paper
• CYP2D6 update: revised nomenclature for CYP2D7/2D6 hybrid genes.

  2012cited by this paper
• Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand.

  2012cited by this paper
• Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy

  2012cited by this paper
• Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen.

  2012cited by this paper
• Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy

  2012influential reference
• CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8

  2012cited by this paper
• Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project

  2012cited by this paper
• A Clinician‐Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical Record

  2012cited by this paper
• Leveraging the electronic health record to implement genomic medicine

  2012cited by this paper
• CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

  2012cited by this paper
• CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

  2012cited by this paper
• Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes

  2011cited by this paper
• Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

  2011cited by this paper
• Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

  2011cited by this paper
• Gene copy number variations: it is important to determine which allele is affected.

  2011cited by this paper
• Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment

  2011cited by this paper
• Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.

  2011cited by this paper
• The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.

  2011cited by this paper
• The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1

  2011cited by this paper
• CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

  2011cited by this paper
• Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.

  2011cited by this paper
• The Emerging Role of Electronic Medical Records in Pharmacogenomics

  2011cited by this paper
• Association between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients with Tamoxifen Treatment

  2011cited by this paper
• CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen.

  2010cited by this paper
• CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

  2010cited by this paper
• CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification

  2010influential reference
• CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction.

  2010cited by this paper
• Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants

  2010cited by this paper
• Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.

  2010cited by this paper
• Robust CYP2D6 genotype assay including copy number variation using multiplex single-base extension for Asian populations.

  2010cited by this paper
• Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy

  2010cited by this paper
• Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment

  2010cited by this paper
• Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

  2010cited by this paper
• No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment.

  2009cited by this paper
• The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.

  2009cited by this paper
• Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

  2009cited by this paper
• Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients

  2008cited by this paper
• The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype

  2008cited by this paper
• Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.

  2008cited by this paper

• The Evolving Landscape of Pharmacogenomics: Current Achievements and Future Directions

  2026cites this paper
• Clinically actionable genetic variation in patients with or at high-risk of cardiovascular diseases from the Montreal Heart Institute.

  2026cites this paper
• Pharmacogenomics and Opioid Efficacy in Sickle Cell Disease

  2026cites this paper
• CYP2D6 Genotyping for Optimization of Tamoxifen Therapy in Indonesian Women with ER+ Breast Cancer

  2025cites this paper
• Novel Pharmacotherapies for Menopausal Symptoms.

  2025cites this paper
• A remotely delivered exercise-based rehabilitation program for patients with persistent chemotherapy-induced peripheral neuropathy (EX-CIPN): Protocol for a phase I feasibility trial

  2025cites this paper
• Clinical Pharmacogenetics: Results After Implementation of Preemptive Tests in Daily Routine

  2025cites this paper
• Impact of Complex Genetic and Drug–Drug Interactions on Tamoxifen Metabolism and Efficacy

  2025cites this paper
• Influence of CYP2D6 polymorphisms on tamoxifen side effects in patients with breast cancer

  2025influential citation
• Solanidine‐derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients

  2025cites this paper
• StarTRAC-CYP2D6: a method for CYP2D6 allele-specific copy number determination using digital PCR

  2025cites this paper
• Pharmacogenetic Testing - Evidence, Challenges, and Pathways to Adoption.

  2025cites this paper
• Evaluation of a targeted next-generation sequencing-based CYP2D6 genotyping method compared with Sanger sequencing and multiplex ligation-dependent probe amplification.

  2025cites this paper
• NFIB rs28379954 does not affect CYP2D6-mediated metabolism of prototypical substrates, tamoxifen or solanidine.

  2025cites this paper
• Expanding biobank pharmacogenomics through machine learning calls of structural variation.

  2025cites this paper
• Advancing Clinical Pharmacogenomics Worldwide Through the Clinical Pharmacogenetics Implementation Consortium (CPIC)

  2025cites this paper
• Long‐Read Sequencing Enhances Pharmacogenomic Profiling by Resolving Complex Haplotypes, Novel Star Alleles, and Structural Variants

  2025cites this paper
• Chemosensitization and Molecular Docking Assessment of Dio-NPs on Resistant Breast Cancer Cells to Tamoxifen

  2025cites this paper
• Unraveling the Impact of Drug Metabolism on Tamoxifen Response in Breast Cancer.

  2025cites this paper
• Idealized Framework for Assisting Pharmacovigilance Reporting in an Ambulatory Primary Care and Chronic Disease Management Clinic

  2025influential citation
• Clinical and pharmacogenomic predictors of survival in tamoxifen treated breast cancer female patients: a real-world study

  2025cites this paper
• Pharmacogenetics in oncology: Unveiling its potential in treatment personalization and beyond.

  2025cites this paper
• Analysis of CYP2D6 Gene Variant Frequencies in Iranian Population

  2025cites this paper
• The effects of tamoxifen and its metabolites on circulating estrogen metabolites among pre- and postmenopausal women.

  2025cites this paper
• Effect of adjuvant endocrine therapy: single-agent vs. switching on breast cancer-free and overall survival — a retrospective cohort study

  2025cites this paper
• From Genotype to Therapeutic Monitoring: Enhancing Tamoxifen Efficacy in Breast Cancer Treatment

  2025cites this paper
• A comprehensive assessment of pharmacogenomic annotation tools for next-generation sequencing data: an emphasis on cyp2d6 and vietnamese genomic data

  2025cites this paper
• Transcriptional Regulation of CYP2D6 by Nrf2 and Its Implications in Breast Cancer Therapy: Bioinformatics and Experimental Evidence

  2025cites this paper
• CYP2D6 polymorphisms and endoxifen concentration in Chinese patients with breast cancer

  2025cites this paper
• Pharmacogenomics in Solid Tumors: A Comprehensive Review of Genetic Variability and Its Clinical Implications

  2025cites this paper
• Drug repurposing for Alzheimer’s disease using a graph-of-thoughts based large language model to infer drug-disease relationships in a comprehensive knowledge graph

  2025cites this paper
• Menopausal hot flashes, night sweats, and insomnia disappeared with lamotrigine: a case report.

  2025cites this paper
• The lack of ESR1 ethnic diversity evidence and its implications for breast cancer personalized treatment

  2025cites this paper
• Prevalence and predictive testing preferences for breast cancer treatment side effects

  2025cites this paper
• Solanidine‐derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients

  2025cites this paper
• Oxybutynin use as a hot flash reducer in breast cancer survivors in the use of tamoxifen: a pilot randomized clinical trial

  2025cites this paper
• Biological sex differences in pharmacokinetics and adverse drug reactions

  2025cites this paper
• Genetic variants in tamoxifen metabolism and early treatment discontinuation among premenopausal breast cancer patients

  2025cites this paper
• Hierarchical RAG enhances a pharmacogenomic AI assistant in guideline related queries

  2025cites this paper
• Analyzing pharmacogenetics cost effectiveness and savings across common health conditions in the United States

  2025cites this paper
• Clinical Pharmacogenetic Testing and Application: 2024 Updated Guidelines by the Korean Society for Laboratory Medicine

  2024cites this paper
• Solanidine Metabolites as Diet‐Derived Biomarkers of CYP2D6‐Mediated Tamoxifen Metabolism in Breast Cancer Patients

  2024cites this paper
• Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes.

  2024cites this paper
• CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108

  2024cites this paper
• An Investigational Study on the Role of CYP2D6, CYP3A4 and UGTs Genetic Variation on Fesoterodine Pharmacokinetics in Young Healthy Volunteers

  2024cites this paper
• The history and future of pharmacogenetics in Aotearoa/New Zealand

  2024cites this paper
• Towards precision cancer medicine for Aboriginal and Torres Strait Islander cancer health equity

  2024cites this paper
• Leveraging in Vitro Models for Clinically Relevant Rare CYP2D6 Variants in Pharmacogenomics

  2024cites this paper
• Integration of a clinical pharmacist practitioner-led pharmacogenomics service in a Veterans Affairs hematology/oncology clinic.

  2024cites this paper
• Pan-cancer single-cell landscape of drug-metabolizing enzyme genes

  2024cites this paper
• THE APPLICATION OF BIOANALYTICAL METHOD OF TAMOXIFEN AND ITS ACTIVE METABOLITES FOR THERAPEUTIC DRUG MONITORING IN BREAST CANCER PATIENTS: A REVIEW

  2024cites this paper
• Genetic Variation in CYP2D6, UGT1A4, SLC6A2 and SLCO1B1 Alters the Pharmacokinetics and Safety of Mirabegron

  2024cites this paper
• CYP2D6 Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis.

  2024cites this paper
• Socio-demographic and genetic risk factors for drug adherence and persistence across 5 common medication classes

  2024cites this paper
• Decoding pharmacogenomic test interpretation and application to patient care

  2024cites this paper
• Endoxifen Concentration Is Associated with Recurrence-Free Survival in Hormone-Sensitive Breast Cancer Patients

  2024cites this paper
• Prevalence of CYP2D6 structural variation in large retrospective study

  2024cites this paper
• Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data

  2024cites this paper
• Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations in Tamoxifen‐Treated Patients from the CEPAM Cohort

  2024cites this paper
• Genetic ancestral patterns in CYP2D6 alleles: structural variants, rare variants, and clinical associations in 479,144 UK Biobank genomes

  2024cites this paper
• Molecular Docking Study on Tamoxifen and Toremifene's Effects on the Breast Cancer Receptors

  2024cites this paper
• Value of Pharmacogenetic Testing Assessed with Real‐World Drug Utilization and Genotype Data

  2024cites this paper
• CYP2D6 copy number determination using digital PCR

  2024cites this paper
• Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug

  2024cites this paper
• Multilevel Mechanisms of Cancer Drug Resistance

  2024cites this paper
• A frequent CYP2D6 variant promotes skipping of exon 3 and reduces CYP2D6 protein expression in human liver samples

  2023cites this paper
• Profiling of pharmacogenomic variants in CYP2D6 and DPYD in indigenous Arab breast cancer patients.

  2023cites this paper
• Using population pharmacokinetic analyses of drugs metabolized by CYP2D6 to study the genotype–phenotype translation

  2023cites this paper
• An Update on Tamoxifen and the Chemo-Preventive Potential of Vitamin E in Breast Cancer Management

  2023cites this paper
• Pharmacogenomic panel testing provides insight and enhances medication management in people with HIV

  2023cites this paper
• The alteration of drug metabolism enzymes and pharmacokinetic parameters in nonalcoholic fatty liver disease: current animal models and clinical practice

  2023cites this paper
• Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes

  2023cites this paper
• The pharmacogenomic landscape of an Indigenous Australian population

  2023cites this paper
• A Comprehensive Analysis of 21 Actionable Pharmacogenes in the Spanish Population: From Genetic Characterisation to Clinical Impact

  2023cites this paper
• Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort

  2023cites this paper
• Pharmacogenomics: current status and future perspectives

  2023cites this paper
• Pharmacogenomics in Asians: Differences and similarities with other human populations

  2023cites this paper
• Genetic Variation in CYP2D6 and SLC22A1 Affects Amlodipine Pharmacokinetics and Safety

  2023cites this paper
• Cross‐Ancestry Genome‐Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations

  2023cites this paper
• PAnno: A pharmacogenomics annotation tool for clinical genomic testing

  2023influential citation
• A crowdsourcing database for the copy-number variation of the Spanish population

  2023cites this paper
• Short-term changes in ultrasound tomography measures of breast density and treatment-associated endocrine symptoms after tamoxifen therapy

  2023cites this paper
• Impact of CYP2D6 and CYP2B6 phenotypes on the response to tramadol in patients with acute post‐surgical pain

  2023cites this paper
• Novel Independent Trans- and Cis-Genetic Variants Associated with CYP2D6 Expression and Activity in Human Livers

  2023cites this paper
• Comprehensive analysis of the role of cuproptosis-related genes in the prognosis and immune infiltration of adrenocortical Carcinoma

  2023cites this paper
• Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer.

  2023cites this paper
• CYP2D6*3, *4, *6 genotypes and endometrial thickness in patients with breast cancer during tamoxifen therapy

  2023cites this paper
• Pharmacogenomic testing in oncology: a health system's approach to identify oncology provider perspectives.

  2023cites this paper
• Socio-demographic and genetic risk factors for drug adherence and persistence: a retrospective nation-wide and biobank study across 5 medication classes and 1 814 521 individuals

  2023cites this paper
• Impact of Sex and Genetic Variation in Relevant Pharmacogenes on the Pharmacokinetics and Safety of Valsartan, Olmesartan and Hydrochlorothiazide

  2023cites this paper
• Effects of pharmacogenetic profiles on pediatric pain relief and adverse events with ibuprofen and oxycodone

  2023cites this paper
• PharmVar Tutorial on CYP2D6 Structural Variation Testing and Recommendations on Reporting

  2023cites this paper
• Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis.

  2023cites this paper
• Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, Endoxifen

  2023cites this paper
• Research progress on tamoxifen and its analogs associated with nuclear receptors.

  2023cites this paper
• Clinical Guidance for Dosing and Monitoring Oral Antihormonal Drugs in Patients with Breast Cancer After Roux-en-Y Gastric Bypass

  2023cites this paper
• Implementation of Pharmacogenetics in First-Line Care: Evaluation of Its Use by General Practitioners

  2023cites this paper
• High-Evidence, Actionable Phenotype Gene Distribution in a Multispecialty, Tertiary Care Clinic: Potentially Actionable Genes and a Referring Department Profile

  2023cites this paper
• Keeping pace with CYP2D6 haplotype discovery: innovative methods to assign function.

  2022cites this paper
• Frequencies of CYP2D6 genetic polymorphisms in Arab populations

  2022cites this paper